(Q45865800)

17 December 2017

title

Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. (English)

1 reference

17 December 2017

main subject

hemophilia

0 references

Coagulation factor VIII

0 references

0 references

10

1 reference

17 December 2017

author name string

E A Chalmers

1

1 reference

17 December 2017

S A Brown

2

1 reference

17 December 2017

D Keeling

3

1 reference

17 December 2017

R Liesner

4

1 reference

17 December 2017

M Richards

5

1 reference

17 December 2017

D Stirling

6

1 reference

17 December 2017

A Thomas

7

1 reference

17 December 2017

V Vidler

8

1 reference

17 December 2017

M D Williams

9

1 reference

17 December 2017

Paediatric Working Party of UKHCDO

11

1 reference

17 December 2017

publication date

1 March 2007

1 reference

17 December 2017

published in

Haemophilia

1 reference

17 December 2017

volume

13

1 reference

17 December 2017

issue

2

1 reference

17 December 2017

page(s)

149-155

1 reference

17 December 2017

Inhibitors in congenital coagulation disorders

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01418.X

The economic impact of factor VIII inhibitors in patients with haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01418.X

Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01418.X

The incidence of inhibitor development according to specific mutations - and treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01418.X

Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01418.X

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01418.X

Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01418.X

Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01418.X

Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01418.X

Factor concentrate prophylaxis for neonates with hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01418.X

What factors influence the age at diagnosis of hemophilia? Results of the French hemophilia cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01418.X

Environmental and genetic factors influencing inhibitor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01418.X

Inhibitors occur more frequently in African-American and Latino haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01418.X

The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01418.X

The epidemiology of inhibitors in haemophilia A: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01418.X

Is the incidence and prevalence of inhibitors greater with recombinant products? Yes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01418.X

Is the incidence and prevalence of inhibitors greater with recombinant products? No.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01418.X

10.1111/J.1365-2516.2006.01418.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017